• Earth Science Tech is a Florida-based company with a vision of enhancing the quality of people’s lives through varied wellness initiatives as part of a growing $4.2 trillion industry
• The company’s two subsidiaries have a targeted focus on helping women who might not normally pursue health care to assess and treat STIs, as well as on utilizing hemp derivatives as therapy for a variety of maladies
• ETST also supports a favored entity’s efforts to gain non-profit status for accepting grants that would further CBD studies and assist the company in donating its products on the basis of need

The health and wellness industry continues to accelerate annual sales of products and philosophies designed to help people live life and love it, propelled in large part by concerns about the rising costs of health care and the decrease in age of patients reporting select chronic ailments, including heart disease. The Global Wellness Institute reports that wellness industry revenues increased by 6.4 percent annually from 2015-17 to become a $4.2 trillion market that is growing nearly twice as fast as the global economy (http://ibn.fm/afG7j).

Florida-based biotech company Earth Science Tech Inc. (OTCQB: ETST) has built a variety of partnerships that support its two wholly owned subsidiaries, as well as a favored non-profit entity, in their endeavors to advance consumers’ wellbeing. The company’s mission is focused on cannabis/industrial hemp and medical devices.

Subsidiary Earth Science Pharmaceutical is committed to bringing low-cost, non-invasive testing processes and vaccines for sexually transmitted infections to market to help women improve the quality of their lives. The company’s first medical device, Hygee, is a home kit designed as a modified panty liner to allow for the self-collection of a gynecological specimen that can be tested for two types of infections – chlamydia and gonorrhea. It gives women the ability to self-collect specimens in a non-clinical setting before sending them to a laboratory that will process the specimens and notify them if they test positive so that they can seek treatment.

The motivation behind the technology is to help women and girls in high-risk situations, who might not be willing or able to seek out assistance through traditional medical care facilities, take responsible action for their own wellbeing with the help of online ordering and home screening.

ETST’s second subsidiary, Cannabis Therapeutics, is investing in the medicinal power of hemp-derived cannabidiol (CBD). Earth Science Tech holds three provisional application patents for a CBD product that the company aims to use in developing treatments for breast and ovarian cancers, and for two generic pharmaceutical drugs with a CBD foundation.

Industrial hemp-based CBD and full-spectrum oils provide the company a core operation with increasing revenues, but Earth Science Tech has also been invested in research and developmental lab work that it hopes to continue for advancing varied high-quality natural hemp extracts and identifying their distinct properties. In addition to breast and ovarian cancer treatments, the company aims to further non-prescription therapies for chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea and general aging-related maladies.

ETST’s formulations are expected to include options such as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs and may include products such as CBD as a natural constituent of hemp oil, vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products (http://ibn.fm/5Hokn).

As a companion entity to Earth Science Tech’s subsidiary operations, the company backs favored entity Earth Science Foundation’s effort to become a non-profit organization that can accept grants and donations to conduct further studies and assist in donating Earth Science Tech’s effective CBD products to those in need.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• Legislative changes and growing demand are forecast to enable the industrial hemp sector to grow at a CAGR of 13.7 percent through 2026
• The worldwide market is expected to eclipse $13 billion within the next seven years
• Such rapid growth is expected to provide strategic expansion opportunities for innovative cultivation equipment suppliers like Sugarmade Inc.

Sugarmade Inc. (OTCQB: SGMD), a major supplier to the booming hydroponic cultivation sector, looks set to benefit from the many opportunities presented by the quickly expanding industrial hemp sector, as statistics indicate that the market is anticipated to reach $13.03 billion by 2026 from $4.63 billion in 2018, expanding at a CAGR of 13.7 percent (http://ibn.fm/fYbkb).

There are several reasons why this market is forecast to expand at such a rapid rate. Hemp is a highly versatile plant that can be cultivated as a renewable source for raw materials utilized by various industries. In addition, hemp is a very lucrative rotation crop due to its ability to detoxify the soil and take in carbon dioxide.

Several subdivisions of the industrial hemp sector are anticipated to grow at a much higher rate than the average. The hemp seed segment, in particular, is expected to grow at a CAGR of 17.1 percent through 2025 – an increase in demand attributed to mounting interest in products like hemp oil and nutraceuticals (http://ibn.fm/b9nyS). Hemp seeds feature approximately 35 percent oil, which is a much-needed resource for the production of various popular products.

The textile industry is also promoting growth, since hemp fiber can be used in the manufacture of fabrics, apparel, fine textiles and accessories. Additionally, the personal care industry is contributing to propelling industrial hemp, with body care products based on hemp growing in prominence as more and more people begin to understand the potential benefits that this resource brings to the table.

Animal care, food and beverages, paper, automotive and other industries come next in the list of sectors promoting the growth of industrial hemp.

All of this growing demand is expected to provide hemp cultivation equipment suppliers with significant strategic business opportunities.

As a major hydroponics cultivation sector supplier that also provides equipment to the hemp industry, Sugarmade expects to tap into these new opportunities to cement its position and continue growing its operations. In April 2019, the company entered into an agreement with Hempistry Inc. to deliver resources for plant micropropagation. The contract is anticipated to remain ongoing as Hempistry expands its operations domestically and internationally.

Legislative changes like the passing of the federal Farm Bill at the end of 2018 have enabled companies like Sugarmade to gain traction in the industrial hemp sector. In Kentucky alone, at least 42,000 acres of hemp will be planted in the near future, Sugarmade CEO Jimmy Chan said in a news release. When all of the other hemp cultivation states are also taken into consideration, it becomes easy to see how demand for quality equipment could multiply rapidly.

Forecasts for 2019 suggest that hydroponics and hemp cultivation are two of the top five agricultural investment trends. Hydroponics techniques can be adapted to many different crop varieties, allowing for more control over the growing environment and higher yields.

For more information, visit the company’s website at www.Sugarmade.com

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR

• CIIX anticipates growth in the Asian region via merger and acquisition activities
• The company’s CEO expects sales to double over the next 12 months
• CIIX’s core business for years has been focused on educational services and delivering financial and investment news in real-time

ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang said, in a Redchip Money Report interview with host Dave Gentry, that investors should know that CIIX is seeking to expand its future business via merger and acquisition activities in the Asian region (http://ibn.fm/SVdPq).

During the interview, Wang projected CIIX’s sales to double over the next 12 months. Wang noted that the company has long been reaching a Chinese-speaking audience in the United States and Canada with investment information on issues ranging from cryptocurrency to CBD.

“We are going to do some merger/acquisition to expand our business in the Asian region,” Wang said in the interview. CIIX is a multifaceted company, driven not only by educational services but also by sales of cosmetics, hemp wine and CBD. At retail, CIIX operates a pop-up store in California at the Glendale Galleria Mall.

CIIX maintains a website, ChineseFN.com, that has a following of more than 100,000 registered users and 5,000 subscribers, according to Wang. The site offers its audience up-to-date analysis on currencies and other financial information.

Wang explained that there are more than four million Chinese Americans and Chinese Canadians in North America, and CIIX plans to expend additional advertising dollars to grow its retail businesses, both online and in-person.

CIIX is a diversified company that offers its audience of Chinese-speaking investors real-time market commentary, analysis and education-related services in Chinese character language sets.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• Wildflower’s sales growth is directly related to its strategic partnerships and the launch of new products
• The company’s CBD-infused products are now available at wellness guru Joel Warren’s ‘The Salon Project’ at Saks Fifth Avenue as part of a continued product offering expansion that began in March 2019
• Wildflower is expected to continue working on new CBD and hemp-derived products in order to solidify its leading market position

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), a Vancouver-based company with an emphasis on plant-based health and wellness products, reported a 78 percent increase in sales for its fiscal quarter ended March 31, 2019, reaching $2.5 million, according to an official company announcement (http://ibn.fm/CAjsA). The growth on a quarterly basis has been an ongoing trend since Wildflower initiated sales of its popular line of hemp CBD products.

Wildflower also announced financial results for City Cannabis Corp. – an entity that Wildflower aims to acquire in the coming weeks. City Cannabis had revenue of $1.8 million for the quarter ended March 31, 2019. The opening of the company’s two stores in January contributed to these favorable financial results. Upon its finalization, the City Cannabis acquisition is expected to be accretive to Wildflower’s earnings.

Apart from announcing its financial results, Wildflower has also released statements about strategic steps undertaken in line with the company’s expansion efforts.

On May 30, 2019, Wildflower announced the launch of the company’s CBD infused products at wellness guru Joel Warren’s ‘The Salon Project’ (http://ibn.fm/OXuIZ). The collaboration will give clients benefiting from the Saks Fifth Avenue salon services an opportunity to experience Wildflower products in a curated shop-in-shop CBD beauty corner.

Celebrity beauty and wellness icon Joel Warren has been a leader in the hair care industry for more than 30 years. His salon focuses on the delivery of a signature experience that brings together the know-how of stylists with the best beauty and wellness products.

This isn’t the first partnership announced by Wildflower in 2019. At the beginning of the year, the company initiated a strategic New York expansion which saw its products become available in more than 20 health and wellness stores throughout Manhattan (http://ibn.fm/r4dBV). New York became a city of focus due to its ability to set global trends. The move quickly paid off, as more than 40 percent of Wildflower’s online sales now come from the New York area.

Over time, Wildflower has been working to expand its product offerings – a strategic initiative that has enabled collaborations like the one with Warren.

In March 2019, the company announced that it was expanding its offerings through the introduction of Pure and Pure Plus tinctures. Both feature hemp-derived CBD, hemp seed oil and milk thistle. The tinctures provide relief from inflammation and support for healthy liver and heart function.

Wildflower announced that it will continue working on new releases as a part of the company’s ongoing product development efforts. The company has also announced plans to expand into Europe’s CBD market via an agreement with Poland-based wellness distribution company Two Towers and an extension of the Omega Rex pharmaceutical chain in the Warsaw area.

“Consumers are drawn to Wildflower because of the effectiveness and range of options available in our product lineup. The strong brand loyalty of Wildflower customers reflects the time and resources invested in our pipeline of products,” CEO William MacLean said in a news release (http://ibn.fm/Kzw6Q).

For more information, visit the company’s website at www.WildflowerBrands.co

NOTE TO INVESTORS: The latest news and updates relating to WLDFF are available in the company’s newsroom at http://ibn.fm/WLDFF

• Plus Products’ brands have seized five spots in a top-10 lineup of California cannabis offerings, including the leading position
• The company plans to expand its product line after recently completing a C$20 million capital raise
• Plus Products has secured an option to purchase Emerald Bay Wellness LLC, a California-based cannabis oil manufacturer

What does it mean when a company has five of the top 10 edible SKUs in the largest cannabis market in the world? It could mean that, like Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), it’s on its way to market control. Plus Products, based in San Mateo, California, has emerged as “the dominant manufacturer of edibles in California, which is no small feat,” according to Chris Parry, a marijuana marketing consultant for Yahoo Finance (http://ibn.fm/2u9fI). It’s no surprise, then, that Plus Products has been ranked as the top cannabis edibles brand in California (http://ibn.fm/F4H9d), and its financials have started to reflect that lofty status. Revenues for Q1 2019 were $3.24 million, marking a 272 percent increase year-over-year.

Plus Products has found a way into the hearts of residents in the Golden State, no doubt because its hugely popular cannabis-infused gummies and mints have found favor with their palates. The latest rankings compiled by data intelligence analyst Headset from retail sales data show the company’s products placing in the tenth, ninth, sixth, second and first positions in the gummy steeplechase (http://ibn.fm/zyDh0). Refresh – Pink Lemonade Gummies (30mg CBD, 70mg THC) was in tenth place; CBD/THC 9:1 Mango Gummies (90mg CBD,10mg THC) was in ninth; Create – Hybrid Sour Blueberry Gummies 20-Pack (100mg) took sixth place; Restore – Indica Blackberry Lemon Gummies 20-Pack (10mg CBD, 90mg THC) was in second; and Sour Watermelon Gummies 20-Pack (100mg) took the top spot. Of the other five places in the top 10, three went to one competitor and two to another.

Since its introduction in 2015, the PLUS brand has climbed to the top of the pack. Its performance reflects a focused strategy. Rather than being all things to all men, Plus Products has gone straight for the palate. PLUS operates through a wholly owned subsidiary, Carberry, and currently has five cannabis-infused gummy candy SKUs (in addition to limited edition SKUs) that are sold in over 200 licensed dispensaries and delivery services. All products under the PLUS brand are produced in the company’s 12,000-square-foot, food-safe cannabis manufacturing facility in Adelanto, California.

Plus Products came to market in October 2018. In an IPO on the Canadian Securities Exchange (CSE), the company offered 6,153,847 subordinate voting shares at a price of C$3.25 per share for total gross proceeds of C$20 million. The company’s shares have since been trading on the CSE under ticker symbol ‘PLUS’. The company intends to use the proceeds of the capital raise for new product development, to increase manufacturing capacity, to upgrade factory automation and to strengthen working capital.

Earlier in June, Plus Products announced that it had acquired an option to purchase Emerald Bay Wellness LLC, a California-based cannabis oil manufacturer. The option grants PLUS the irrevocable right, but not the obligation, to purchase all of the business assets of Emerald Bay Extracts for cash and stock consideration (http://ibn.fm/cHQUR).

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF

• Exclusive joint development agreement with Noramco, the world’s largest producer of chemically synthesized cannabinoids and pharmaceutical APIs, to commercialize biosynthesized CBD
• Willow is fully funded with $37 million and expects to have more than $15 million on the balance sheet once the biosynthesized CBD isolate is ready to sell as a product
• Experienced research team with historical expertise in developing a biosynthesized API derived from the opium poppy, from the bench level to commercial scale-up
• Established laboratories in Calgary and Vancouver, Canada, and in San Francisco, all undergoing expansion
• U.S. CBD market potential in excess of $66 billion by 2025 for cannabinoid-based APIs and CBD consumer retail goods

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://ibn.fm/G10ML) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

For more information, visit the company’s website at www.WillowBio.com

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW

• The cost of foodborne illnesses in the U.S. is estimated at more than $15.6 billion, with one in six Americans falling ill and roughly 3,000 dying from contaminated food and beverages annually
• High pressure processing plays an important role in food safety and is currently a $20 billion market; it is projected to reach $42 billion by 2026
• Independent research shows that PBIO’s Pressure Cycling Technology equipment can be used to dramatically reduce or eliminate common and well-known foodborne disease-causing bacteria
• The company’s new Ultra Shear Technology platform is being developed to make long-shelf-life milk and other dairy products
• Its Ultra Shear Technology has also been shown to make CBD oil “naturally” water soluble

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables and related services for the global life sciences and other industries worldwide, marked the first-ever World Food Safety Day by sharing several positive independent reports showing that its unique and patented pressure cycling technology (“PCT”) equipment is a formidable adversary when it comes to eliminating foodborne pathogens.

World Food Safety Day, an event adopted by the United Nations General Assembly and supported by international public health organizations including the U.S. Food and Drug Administration, took place on June 7, 2019 (http://ibn.fm/6hvQv). Several research presentations featuring PBIO’s HUB440 and HUB880 Explorer systems were delivered at the Institute of Food Technologists conference, an annual food science event held June 2-5, 2019, in New Orleans, Louisiana. Presentations centered on the use of PBIO’s unique, ultra-high pressure, PCT-based HUB equipment and the promising effect it has in high pressure processing food applications to inactivate foodborne pathogens.

Dr. Aliyar Fouladkhah, assistant professor and director of the Public Health Microbiology Laboratory at Tennessee State University, showed in a well-attended presentation that PBIO’s ultra-high pressure equipment can be used to dramatically reduce common and well-known foodborne disease-causing bacteria such as E.coli 0157 and Listeria monocytogenes, which are found in the presence of foods such as apple cider and chopped meat.

“Members of my public health microbiology research group and I were able to conduct and present results from our cutting-edge, innovative research projects to the most respected international food science conference thanks to the consistency, accuracy, and precision of PBIO’s HUB high pressure units and the collaborative endeavors with PBIO engineers and research scientists,” Fouladkhah stated in a news release (http://ibn.fm/PDu2F).

FDA Deputy Commissioner for Food Policy and Response Frank Yiannas said during his World Food Safety Day comments that, “Foodborne pathogens do not recognize boundaries or borders,” adding that approximately 125,000 children under the age of five die each year around the world because of foodborne illnesses (http://ibn.fm/V7Z6s). The U.S. Department of Agriculture estimates that the cost of foodborne illnesses in the U.S. is more than $15.6 billion annually (http://ibn.fm/P0RQE).

“The need for safer food is a worldwide concern,” Richard T. Schumacher, president and CEO of PBIO, stated. “We believe that presentations such as Dr. Fouladkhah’s at this year’s IFT Conference will help generate awareness of our new, powerful yet affordable bench-top HUB family of products in the food industry, government, military, and academic laboratory environment, and that this added exposure will result in an increased demand for our HUB equipment in this large and growing market.”

The company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT (pressure cycling technology) systems in over 200 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology.

In addition to the 17 or so patents that PBIO holds on its PCT platform, it also holds two patents in China for a second pressure-based technology – its novel Ultra Shear Technology (UST) platform. Patents have also been filed in the U.S. and many other countries worldwide. UST is a novel process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two or more insoluble liquids (like oil and water) soluble. UST is based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

Over the past few months, PBIO has released two short videos (http://ibn.fm/kVEML and http://ibn.fm/Mh3dc) showing how its patented UST platform was able to process CBD plant oil into a water-soluble nanoemulsion. When the UST-processed CBD oil was added to different liquids – such as a soft drink, a sports drink and a beer – the nanoemulsified CBD oil completely dissolved in each liquid.

UST holds great promise for many applications, such as making long-shelf-life stable milk and other dairy products, safer and better tasting beverages, and significantly more soluble and bioavailable CBD for use in foods, beverages, ointments and gels.

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• Wildflower Brands has signed an agreement with City Cannabis Corp. to acquire its issued and outstanding shares
• City Cannabis has been called the “fastest-growing multiple location cannabis retailer” in British Columbia
• Acquisition of shares is anticipated by leadership at both companies

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), a Vancouver-based company developing and designing brands focusing on plant-based health and wellness products, has signed a share agreement with City Cannabis Corp. in order to acquire all of the issued and outstanding shares of City Cannabis (http://ibn.fm/4sHNR).

City Cannabis is continuing to grow, expanding its reach into the Vancouver cannabis market. The company is in the process of opening its fourth licensed dispensary in Vancouver, and its management team continues to examine other possible locations across the country. Currently, the company holds nine leases at varying stages of the regulatory licensing process.

Consideration for the acquisition consists of 60 million common shares of the company at a deemed price of $0.75 per common share. Wildflower’s acquisition of City Cannabis’ shares strengthens Wildflower’s status as an industry leader and brand-focused cannabis company.

“City Cannabis is no doubt the fastest-growing, multiple location cannabis retailer in British Columbia,” Wildflower CEO William MacLean stated in a news release. He referenced the acuity of the City Cannabis team in identifying key dispensary locations, as well as its industry knowledge and ability to work with all levels of regulators. “We look forward to completing the acquisition and bringing together two phenomenal companies,” he added.

“This is an exciting moment for everyone, and we are thrilled to be joining the Wildflower team,” said City Cannabis CEO Krystian Wetulani. “We believe Wildflower’s branding and marketing expertise will drive growth once City Cannabis is integrated, resulting in significant long-term value to Wildflower shareholders.”

Wildflower Brands utilizes a comprehensive business model that encompasses research and development, manufacturing, distribution, marketing and retail. The company’s holdings include Wildflower Wellness, which offers a complete line of full-spectrum, CBD extract-infused products; King Extracts, a California-based company focused on cannabis technology and delivery systems; and licenses in Los Angeles and California to operate cultivation, manufacturing, distribution, retail and delivery.

City Cannabis is a cannabis retailer holding two of the six City of Vancouver licenses in the province of British Columbia. The company has been turning a profit in dispensary operation since Vancouver started licensing cannabis retailers. Upon closing of the share acquisition, Wildflower intends to appoint Wetulani as a director and chief development officer.

For more information, visit the company’s website at www.WildflowerBrands.co

NOTE TO INVESTORS: The latest news and updates relating to WLDFF are available in the company’s newsroom at http://ibn.fm/WLDFF

• A partnership with PAX will allow Organigram to manufacture and fill pods for the premium, technology-based PAX Era vaporizer
• The PAX partnership is expected to enable the two entities to seize new opportunities on the market and work together to develop premium products featuring disruptive, industry-leading technology that is set to redefine the experience of vaping
• An agreement signed with Feather Company Ltd. makes Organigram the exclusive Canadian supplier of unique and proprietary vaporizer pen technology
• Organigram is selling to all 10 Canadian provinces
• The company is on track to increase production capacity and is well positioned for Canada’s new edibles and derivative legislation, slated for October 2019

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI), a leading Canadian licensed producer (LP) of high-quality cannabis and extract-based products, continues to develop exclusive partnerships and introduce innovative products that enhance the cannabis lifestyle for its customers. An exclusive agreement signed with Feather Company Ltd. illustrates this laser focus on customer experience as Organigram looks forward to Canada’s legalization of new cannabis product categories, as the company stated in a news release (http://ibn.fm/T4kfV).

“A successful recreational cannabis market requires that licensed producers and their partners continually reimagine the cannabis experience,” Ray Gracewood, senior vice president, marketing and communications for Organigram, stated in the release. “It is critical for Organigram to find unique ways to offer customers the kind of value that will help differentiate our brands. The future is in providing unique opportunities for customers to explore the product.”

The exclusive agreement between Organigram and Feather, a cannabis innovator and lifestyle brand committed to the production of premium-quality products, creates a mutually beneficial relationship for the two companies. Organigram, through its Edison Cannabis Co. brand, will hold an exclusive license to Feather’s proprietary vaporizer pen technology and form factor. Organigram will also represent Feather across Canada from a commercial perspective and plans to approach all 10 provinces with Feather’s disposable and cartridge-based units.

“We are thrilled to be working with Organigram,” Feather CEO Patrick Lehoux stated in the release. “As patients, enthusiasts and advocates for the cannabis community, we are committed to applying our diverse skills to produce the best experience for consumers. Our partnership with Organigram opens new and exciting opportunities for us to do just that. We believe in the Edison brand and Organigram’s best-in-class facility ensures that we are partnered with a team committed to producing a consistent, premium product.”

The disposable vaporizer pen and 5/10 thread cartridges for targeted adult-use customer segments are expected to be available as this product category becomes legal in Canada by mid-October 2019. Feather’s technology and hardware offers Organigram’s Edison brand a unique, proprietary delivery mechanism for discerning and sophisticated consumers and will complement the company’s partnership with PAX, a leader in closed-loop vaporizable technology offered through the PAX Era product line  (http://ibn.fm/lXIpJ).

Organigram is planning on working with and offering the Edison Cannabis Co.-branded PAX Era pods to all 10 of its provincial partners to achieve coast-to-coast distribution. The pods will be filled onsite at Organigram’s Moncton facility at the company’s phase 5 refurbishment.

As concentrates are anticipated to become legal in Canada later in 2019, giving birth to a wide range of new market development opportunities, strategic partnerships like the one between Organigram and PAX Labs are expected to allow the immediate launch of premium products featuring a disruptive, industry-leading technology that is set to redefine the experience of vaping.

“Cannabis 2.0 – the next generation of legal, adult use cannabis products – represents a world of opportunity,” Organigram CEO Greg Engel added. “Innovative partnerships with exceptional companies like PAX mean our own product offering grows and our customers have access to cutting-edge technology and cannabis experiences.”

The agreement with PAX reflects Organigram’s strategic commitment to growth and leadership through technology-driven innovation. Additionally, the company has been building up significant levels of concentrate in anticipation of the Canadian legislative change and the launch of Cannabis 2.0 vape pens and edibles later in 2019. According to Engel, this is just the beginning for his company, whose team is strongly committed to developing exceptional and imaginative products that support both the organization’s business objectives and its customers’ needs.

Further cementing its position, Organigram earlier in 2019 secured distribution agreements in all 10 Canadian provinces, becoming one of just three licensed producers in Canada to do so (http://ibn.fm/NCowK). The company boasts the lowest cost of cultivation among Canadian licensed producers, driven by industry-leading yields.

For more information, visit the company’s website at www.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• CIIX is the first CBD company to focus on Chinese-speaking North Americans
• The company is targeting a huge market opportunity in China and throughout Asia
• CIIX sales are projected to double over the next 12 months

ChineseInvestors.com Inc. (OTCQB: CIIX) provides Chinese-speaking investors in the U.S., Canada and Asia with real-time market commentary, analysis and education-related services in the Chinese language. The company has a highly diversified revenue stream and is seeing a huge market opportunity for its cannabinoid products, as well as expanding into cryptocurrency and blockchain educational services.

In 2019, CIIX experienced an 81 percent revenue increase, which CEO Warren Wang attributed mainly to the company’s hemp CBD sales. The company is standing at the forefront of this market as the first CBD company to focus on the more than four million Chinese-speaking Americans and Canadians.

On May 1, 2019, under wholly owned subsidiary ChineseHempOil.com, which has been doing business in the United States since 2017 as Chinese Wellness Center (CWC), the company opened its first mall pop-up kiosk. The kiosk offers customers CWC’s OptHemp product line and additional CBD products including NuLeaf Naturals, Joy Organics, Medterra, Hemp Meds and Medix.

Right now, a huge market opportunity exists in China and throughout Asia. The Chinese consumer has high spending power, and regulations are in favor of CBD products in China. CIIX reports additional mergers and acquisitions in the planning stages in Asia.

By focusing on the American market and opportunities in China and Asia, the company’s sales are projected to double over the next 12 months, Wang noted in a news release (http://ibn.fm/2UeEH). U.S. consumer sales of CBD are anticipated to reach $1.8 billion by 2022, increasing drastically from the $500 million seen in 2018 (http://ibn.fm/q72dL). The industry is rapidly growing, and CIIX has positioned itself strategically as the first publicly traded Chinese company to offer CBD to an American market.

CIIX’s main focus is on providing financial information and services to the global Chinese community. The company continues to develop and market web-based tools to educate and inform while providing added value to an everchanging market. The following educational tools are provided in the Chinese language character set:

• Da Ma Dian Ping is a cannabis-focused mobile app that’s currently in the developmental stage. This app will aim to provide Chinese speakers worldwide with the ability to review and discuss cannabis products.
• www.NewCoins168.com is a free portal that offers news and investment education covering cryptocurrency and blockchain.
• www.ChineseInvestors.com is the company’s primary site, offering real-time market information and educational services.
• www.ChineseFN.com offers daily financial investment news and has 5,000 subscribers and more than 100,000 registered users.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX